Lai Wang
Chief Tech/Sci/R&D Officer at BEIGENE, LTD.
Net worth: 20 M $ as of 2024-03-30
Profile
Mr. Lai Wang is a Global Head-Research & Development at BeiGene Ltd.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BEIGENE LTD
0.13% | 2023-06-25 | 1,658,215 ( 0.13% ) | 20 M $ | 2024-03-30 |
Lai Wang active positions
| Companies | Position | Start |
|---|---|---|
| BEIGENE, LTD. | Chief Tech/Sci/R&D Officer | 2021-03-31 |
Former positions of Lai Wang
| Companies | Position | End |
|---|---|---|
Joyant Pharmaceuticals, Inc.
 Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Corporate Officer/Principal | - |
Training of Lai Wang
| Fudan University | Undergraduate Degree |
| University of Texas Health Science Center at Houston | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BEIGENE, LTD. | Health Technology |
| Private companies | 1 |
|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
- Stock Market
- Insiders
- Lai Wang
